[Fatty acid composition and parameters of VLDL and LDL in persons with dyslipidemia].
Oxidatively modified LDL play an important role in the pathogenesis of endothelial dysfunction, initiation and development of atherosclerosis and stability of the atheromatous plaque. The increased oxidative stress is apparent from a number of deviations, which are part of the insulin resistance syndrome (hypertension, hypoalphacholesterolaemia, diabetes and hyperlipoproteinaemia). The objective of the work was to examine the degree of oxidation and oxidability of LDL and VDL in subjects with dyslipidaemia. In 40 subjects with dyslipidaemia, defined as a triglyceride concentration above 2.30 mmol/l and a drop of HDL cholesterol below 0.90 mmol/l, the authors assessed the fatty acid profile in plasma lipid classes and LDL by capillary gas chromatography. Lipoperoxidation in VLDL and LDL was examined by the method of kinetics of conjugated dienes according to Esterbauser. The results were compared with a group of healthy controls. The group of dyslipidaemic subjects had higher concentrations of NEFA, IRI, blood sugar and uric acid. In these subjects the concentration of conjugated dienes in VLDL was significantly higher and the lag stage in VLDL and LDL was reduced. Both groups differed as to the composition of VLDD and LDL. The group of dyslipidaemic subjects had a higher concentration of cholesterol, phospholipids, triglycerides and apolipoprotein B. A constant finding in the fatty acid profile of all lipid classes was a raised concentration of palmitoleic acid and reduced linoleic acid concentration. Dyslipidaemic subjects have, as compared with a control group, higher NEFA, IRI and uric acid concentrations. Furthermore they differed not only by the composition of VLDL and LDL but also by a higher degree of VLDL oxidation and reduced resistance to lipoperoxidation of VLDL and LDL particles. A consistent finding in the fatty acid profile was an increased level of palmitoleic acid in all plasma lipid classes and LDL and a drop of linoleic acid in phosphatidylcholine LDL and plasma cholesterolesters.